ArticleMedicine2025
Uric acid-to-high-density lipoprotein ratio and diabetes mellitus in stroke survivors: A cross-sectional analysis of NHANES 1998 to 2018.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of the Relationship Between Glycemic Control and Inflammation-Nutrition Indices in Older Adults with Type 2 Diabetes.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetes mellitus (DM) significantly elevates cerebrovascular risk in stroke survivors, yet metabolic predictors specific to this population remain underexplored. The uric acid-to-high-density lipoprotein cholesterol ratio (UHR) encapsulates pro-oxidant and anti-atherogenic pathways relevant to DM pathogenesis, but its clinical utility in stroke cohorts is unestablished. This cross-sectional study analyzed 1999 to 2018 National Health and Nutrition Examination Survey data from 964 adults with stroke history (representing 3,481,079 U.S. adults). UHR was standardized into sex-stratified z-scores. DM was defined by American Diabetes Association criteria. Generalized variance inflation factors (GVIF) confirmed absence of multicollinearity (all GVIF(1/(2*Df)) < 5). Weighted multivariable logistic regression assessed UHR-DM associations across 3 models: unadjusted (model 1), sex/age-adjusted (model 2), and fully adjusted for clinical covariates (model 3). Restricted cubic splines evaluated nonlinearity, piecewise regression identified effect thresholds, and time-dependent receiver operating characteristic analysis assessed predictive performance with inverse probability weighting. Mediation analysis quantified body mass index (BMI)'s intermediary role. Elevated UHR z-scores demonstrated dose-dependent DM associations, with quartile 4 (Q4) exhibiting 3.12-fold higher odds (95% confidence interval [CI]: 1.86-5.25, P < .001) in model 3. Restricted cubic splines revealed significant nonlinearity (P < .05), identifying UHR z-score = -0.419 (raw value = 0.088) as an inflection point: below this threshold, each 1-unit increase conferred 3.39-fold higher DM risk (95% CI: 1.56-7.40, P = .002); above it, risk increased 1.20-fold (95% CI: 1.08-1.45, P = .041). BMI mediated 38% of the total effect (β = 0.04, 95% CI: 0.03-0.06; P < .001). A rea under the curve (AUC) for UHR z-scores predicting DM improved from 0.61 (unadjusted) to 0.68 (model 3-adjusted). Subgroup analyses showed effect modification by sex (P for interaction < .05). In stroke survivors, UHR elevation independently suggests DM risk through threshold-dependent mechanisms, with BMI mediating over one-third of this relationship. UHR assessment could enhance DM risk stratification in poststroke care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.